PI3K Inhibitor Compounds Selective Isoform Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents are inadequate in selectively inhibiting PI3K isoforms, which are implicated in various diseases such as cancer and autoimmune disorders, due to their non-specific activity and limited efficacy.
Innovation Solution
Development of novel compounds with specific structures that selectively inhibit PI3K isoforms, including pharmaceutical compositions and methods for their use in treating diseases mediated by these enzymes, such as cancer and autoimmune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents are used to inhibit PI3K isoforms, then some inhibitory effect is achieved, but the agents lack selectivity and have limited efficacy
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (substituents at positions R1, R2, R3, R4, R5, R6 on the pyrimidine ring system) that confer selective affinity for particular PI3K isoforms. Different substituent patterns enable the same core structure to selectively target PI3Kα, PI3Kβ, PI3Kδ, or PI3Kγ, thus achieving isoform-specific inhibition without requiring different molecular frameworks.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters (substituent types, positions, and configurations) of the pyrimidine core structure to modulate selectivity and efficacy. By changing parameters such as the nature of substituents at R1-R6 positions and the values of n and m, the patent optimizes compound properties to achieve selective inhibition of specific PI3K isoforms while maintaining therapeutic effectiveness.
2Object-affected harmful factors
If non-specific PI3K inhibitors are used, then broad PI3K activity is reduced, but off-target effects and limited therapeutic benefit occur
Solution Approach 1:
The patent applies segmentation by dividing the PI3K inhibitor development into distinct selective pathways targeting different isoforms (α, β, δ, γ). The pyrimidine core structure serves as a segmented platform where specific substituent patterns can be assigned to target specific isoforms, enabling selective inhibition that avoids off-target effects on non-targeted PI3K family members while maintaining therapeutic benefit through isoform-specific mechanisms.
Data Source
AI summary
The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof wherein n, m, R1, R2, R3, R4, and R5 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (ΡI3Κ) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more ΡI3Κ isoforms.